Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jul 3;83(3):366–374. doi: 10.1054/bjoc.2000.1260

Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport

R Evers 1,2, M Kool 1,3, A J Smith 1,4, L van Deemter 1, M de Haas 1, P Borst 1
PMCID: PMC2374556  PMID: 10917553

Abstract

The human multidrug transporter MDR1 P-glycoprotein and the multidrug resistance proteins MRP1 and MRP2 transport a range of cytotoxic drugs, resulting in multidrug resistance in tumour cells. To overcome this form of drug resistance in patients, several inhibitors (reversal agents) of these transporters have been isolated. Using polarized cell lines stably expressing human MDR1, MRP1 or MRP2 cDNA, and 2008 ovarian carcinoma cells stably expressing MRP1 cDNA, we have investigated in this study the specificity of the reversal agents V-104 (a pipecolinate derivative), GF120918 (an acridone carboxamide derivative also known as GG918), and Pluronic L61 (a (poly)oxypropethylene and (poly)oxypropylene block copolymer). Transport experiments with cytotoxic drugs with polarized cell lines indicate that all three compounds efficiently inhibit MDR1 Pgp. Furthermore, V-104 partially inhibits daunorubicin transport by MRP1 but not vinblastine transport by MRP2. V-104 reverses etoposide resistance of 2008/MRP1 cells, whereas GF120918 does not reverse resistance due to MRP1. V-104 partially inhibits the export of the organic anion dinitrophenyl S -glutathione by MDCKII-MRP1 but not by MDCKII-MRP2 cells. Unexpectedly, export of the organic anion calcein by MDCKII-MRP1 and MDCKII-MRP2 cells is stimulated by Pluronic L61, probably because it relieves the block on entry of calcein AM into the cell by endogenous MDR1 Pgp. © 2000 Cancer Research Campaign

Keywords: multidrug resistance, reversal agent, MRP1, multispecific organic anion transporter, MDR1 Pgp, polarized cell

Full Text

The Full Text of this article is available as a PDF (114.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bakos E., Evers R., Szakács G., Tusnády G. E., Welker E., Szabó K., de Haas M., van Deemter L., Borst P., Váradi A. Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J Biol Chem. 1998 Nov 27;273(48):32167–32175. doi: 10.1074/jbc.273.48.32167. [DOI] [PubMed] [Google Scholar]
  2. Batrakova E. V., Dorodnych T. Y., Klinskii E. Y., Kliushnenkova E. N., Shemchukova O. B., Goncharova O. N., Arjakov S. A., Alakhov V. Y., Kabanov A. V. Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. Br J Cancer. 1996 Nov;74(10):1545–1552. doi: 10.1038/bjc.1996.587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Batrakova E. V., Han H. Y., Miller D. W., Kabanov A. V. Effects of pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells. Pharm Res. 1998 Oct;15(10):1525–1532. doi: 10.1023/a:1011942814300. [DOI] [PubMed] [Google Scholar]
  4. Böhme M., Büchler M., Müller M., Keppler D. Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett. 1993 Oct 25;333(1-2):193–196. doi: 10.1016/0014-5793(93)80403-h. [DOI] [PubMed] [Google Scholar]
  5. Chen Z. S., Kawabe T., Ono M., Aoki S., Sumizawa T., Furukawa T., Uchiumi T., Wada M., Kuwano M., Akiyama S. I. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol. 1999 Dec;56(6):1219–1228. doi: 10.1124/mol.56.6.1219. [DOI] [PubMed] [Google Scholar]
  6. Cole S. P., Bhardwaj G., Gerlach J. H., Mackie J. E., Grant C. E., Almquist K. C., Stewart A. J., Kurz E. U., Duncan A. M., Deeley R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992 Dec 4;258(5088):1650–1654. doi: 10.1126/science.1360704. [DOI] [PubMed] [Google Scholar]
  7. Cole S. P., Deeley R. G. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays. 1998 Nov;20(11):931–940. doi: 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  8. Cui Y., König J., Buchholz J. K., Spring H., Leier I., Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol. 1999 May;55(5):929–937. [PubMed] [Google Scholar]
  9. Evers R., Cnubben N. H., Wijnholds J., van Deemter L., van Bladeren P. J., Borst P. Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Lett. 1997 Dec 8;419(1):112–116. doi: 10.1016/s0014-5793(97)01442-7. [DOI] [PubMed] [Google Scholar]
  10. Evers R., Kool M., van Deemter L., Janssen H., Calafat J., Oomen L. C., Paulusma C. C., Oude Elferink R. P., Baas F., Schinkel A. H. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest. 1998 Apr 1;101(7):1310–1319. doi: 10.1172/JCI119886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Evers R., Zaman G. J., van Deemter L., Jansen H., Calafat J., Oomen L. C., Oude Elferink R. P., Borst P., Schinkel A. H. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest. 1996 Mar 1;97(5):1211–1218. doi: 10.1172/JCI118535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Evers R., de Haas M., Sparidans R., Beijnen J., Wielinga P. R., Lankelma J., Borst P. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375–383. doi: 10.1054/bjoc.2000.1262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Feller N., Broxterman H. J., Währer D. C., Pinedo H. M. ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FEBS Lett. 1995 Jul 17;368(2):385–388. doi: 10.1016/0014-5793(95)00677-2. [DOI] [PubMed] [Google Scholar]
  14. Fisher G. A., Sikic B. I. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am. 1995 Apr;9(2):363–382. [PubMed] [Google Scholar]
  15. Germann U. A., Ford P. J., Shlyakhter D., Mason V. S., Harding M. W. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs. 1997 Feb;8(2):141–155. doi: 10.1097/00001813-199702000-00005. [DOI] [PubMed] [Google Scholar]
  16. Germann U. A., Shlyakhter D., Mason V. S., Zelle R. E., Duffy J. P., Galullo V., Armistead D. M., Saunders J. O., Boger J., Harding M. W. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs. 1997 Feb;8(2):125–140. doi: 10.1097/00001813-199702000-00004. [DOI] [PubMed] [Google Scholar]
  17. Gottesman M. M., Hrycyna C. A., Schoenlein P. V., Germann U. A., Pastan I. Genetic analysis of the multidrug transporter. Annu Rev Genet. 1995;29:607–649. doi: 10.1146/annurev.ge.29.120195.003135. [DOI] [PubMed] [Google Scholar]
  18. Hirohashi T., Suzuki H., Sugiyama Y. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem. 1999 May 21;274(21):15181–15185. doi: 10.1074/jbc.274.21.15181. [DOI] [PubMed] [Google Scholar]
  19. Holló Z., Homolya L., Hegedüs T., Sarkadi B. Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells. FEBS Lett. 1996 Mar 25;383(1-2):99–104. doi: 10.1016/0014-5793(96)00237-2. [DOI] [PubMed] [Google Scholar]
  20. Homolya L., Holló M., Müller M., Mechetner E. B., Sarkadi B. A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells. Br J Cancer. 1996 Apr;73(7):849–855. doi: 10.1038/bjc.1996.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hooijberg J. H., Broxterman H. J., Kool M., Assaraf Y. G., Peters G. J., Noordhuis P., Scheper R. J., Borst P., Pinedo H. M., Jansen G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999 Jun 1;59(11):2532–2535. [PubMed] [Google Scholar]
  22. Hyafil F., Vergely C., Du Vignaud P., Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993 Oct 1;53(19):4595–4602. [PubMed] [Google Scholar]
  23. Jedlitschky G., Leier I., Buchholz U., Hummel-Eisenbeiss J., Burchell B., Keppler D. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem J. 1997 Oct 1;327(Pt 1):305–310. doi: 10.1042/bj3270305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Juliano R. L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976 Nov 11;455(1):152–162. doi: 10.1016/0005-2736(76)90160-7. [DOI] [PubMed] [Google Scholar]
  25. Keppler D., Jedlitschky G., Leier I. Transport function and substrate specificity of multidrug resistance protein. Methods Enzymol. 1998;292:607–616. doi: 10.1016/s0076-6879(98)92047-x. [DOI] [PubMed] [Google Scholar]
  26. Kool M., de Haas M., Scheffer G. L., Scheper R. J., van Eijk M. J., Juijn J. A., Baas F., Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997 Aug 15;57(16):3537–3547. [PubMed] [Google Scholar]
  27. Kool M., van der Linden M., de Haas M., Baas F., Borst P. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res. 1999 Jan 1;59(1):175–182. [PubMed] [Google Scholar]
  28. Leier I., Jedlitschky G., Buchholz U., Cole S. P., Deeley R. G., Keppler D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem. 1994 Nov 11;269(45):27807–27810. [PubMed] [Google Scholar]
  29. Loe D. W., Almquist K. C., Deeley R. G., Cole S. P. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem. 1996 Apr 19;271(16):9675–9682. doi: 10.1074/jbc.271.16.9675. [DOI] [PubMed] [Google Scholar]
  30. Loe D. W., Deeley R. G., Cole S. P. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. 1998 Nov 15;58(22):5130–5136. [PubMed] [Google Scholar]
  31. Masuda M., I'izuka Y., Yamazaki M., Nishigaki R., Kato Y., Ni'inuma K., Suzuki H., Sugiyama Y. Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res. 1997 Aug 15;57(16):3506–3510. [PubMed] [Google Scholar]
  32. Miller D. W., Batrakova E. V., Kabanov A. V. Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers. Pharm Res. 1999 Mar;16(3):396–401. doi: 10.1023/a:1018873702411. [DOI] [PubMed] [Google Scholar]
  33. Miller D. W., Batrakova E. V., Waltner T. O., Alakhov VYu, Kabanov A. V. Interactions of pluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption. Bioconjug Chem. 1997 Sep-Oct;8(5):649–657. doi: 10.1021/bc970118d. [DOI] [PubMed] [Google Scholar]
  34. Nerurkar M. M., Ho N. F., Burton P. S., Vidmar T. J., Borchardt R. T. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J Pharm Sci. 1997 Jul;86(7):813–821. doi: 10.1021/js960483y. [DOI] [PubMed] [Google Scholar]
  35. Oude Elferink R. P., Bakker C. T., Jansen P. L. Glutathione-conjugate transport by human colon adenocarcinoma cells (Caco-2 cells). Biochem J. 1993 Mar 15;290(Pt 3):759–764. doi: 10.1042/bj2900759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Rappa G., Lorico A., Flavell R. A., Sartorelli A. C. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res. 1997 Dec 1;57(23):5232–5237. [PubMed] [Google Scholar]
  37. Rowinsky E. K., Smith L., Wang Y. M., Chaturvedi P., Villalona M., Campbell E., Aylesworth C., Eckhardt S. G., Hammond L., Kraynak M. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol. 1998 Sep;16(9):2964–2976. doi: 10.1200/JCO.1998.16.9.2964. [DOI] [PubMed] [Google Scholar]
  38. Sarkadi B., Müller M. Search for specific inhibitors of multidrug resistance in cancer. Semin Cancer Biol. 1997 Jun;8(3):171–182. doi: 10.1006/scbi.1997.0069. [DOI] [PubMed] [Google Scholar]
  39. Schinkel A. H., Wagenaar E., van Deemter L., Mol C. A., Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995 Oct;96(4):1698–1705. doi: 10.1172/JCI118214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Schuetz J. D., Connelly M. C., Sun D., Paibir S. G., Flynn P. M., Srinivas R. V., Kumar A., Fridland A. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med. 1999 Sep;5(9):1048–1051. doi: 10.1038/12487. [DOI] [PubMed] [Google Scholar]
  41. Smith A. J., Mayer U., Schinkel A. H., Borst P. Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. J Natl Cancer Inst. 1998 Aug 5;90(15):1161–1166. doi: 10.1093/jnci/90.15.1161. [DOI] [PubMed] [Google Scholar]
  42. Szabó K., Welker E., Bakos, Müller M., Roninson I., Váradi A., Sarkadi B. Drug-stimulated nucleotide trapping in the human multidrug transporter MDR1. Cooperation of the nucleotide binding domains. J Biol Chem. 1998 Apr 24;273(17):10132–10138. doi: 10.1074/jbc.273.17.10132. [DOI] [PubMed] [Google Scholar]
  43. Twentyman P. R., Bleehen N. M. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. Eur J Cancer. 1991;27(12):1639–1642. doi: 10.1016/0277-5379(91)90435-g. [DOI] [PubMed] [Google Scholar]
  44. Venne A., Li S., Mandeville R., Kabanov A., Alakhov V. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res. 1996 Aug 15;56(16):3626–3629. [PubMed] [Google Scholar]
  45. Wallstab A., Koester M., Böhme M., Keppler D. Selective inhibition of MDR1 P-glycoprotein-mediated transport by the acridone carboxamide derivative GG918. Br J Cancer. 1999 Mar;79(7-8):1053–1060. doi: 10.1038/sj.bjc.6690169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Yanagisawa T., Newman A., Coley H., Renshaw J., Pinkerton C. R., Pritchard-Jones K. BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma. Br J Cancer. 1999 Jun;80(8):1190–1196. doi: 10.1038/sj.bjc.6990485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Zaman G. J., Flens M. J., van Leusden M. R., de Haas M., Mülder H. S., Lankelma J., Pinedo H. M., Scheper R. J., Baas F., Broxterman H. J. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8822–8826. doi: 10.1073/pnas.91.19.8822. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES